Hepatitis C virus (HCV) NS3/4A protease inhibitors play an important role in several of the combination regimens that have revolutionized the treatment of this disease, offering patients an excellent chance for a complete cure. Starting from inhibitors incorporating oxime-based P*-shelf moieties, a collaborative effort between Abbott Laboratories and Enanta Pharmaceuticals generated ABT-450 (paritaprevir, a component of Technivie™ and Viekira Pak™), incorporating novel P*-phenanthridine and P3-amide capping groups and pharmacokinetically boosted by ritonavir. The discovery and development of ABT-450 enabled one of the first IFN-free combination therapies for HCV genotype 1 infection and contributed to the transformation of the treatment of this chronic and deadly disease.
This is a preview of subscription content, log in to check access.
The authors would like to acknowledge the assistance of Tami Pilot-Matias (virology discussions), Charles Hutchins (molecular modeling support), and Lisa Hasvold (proofreading) in the preparation of this manuscript.
Compliance with Ethical Standards
The study was supported by AbbVie.
Conflict of Interest
K.F.M., Y.-Y.K, H.-J.C., J.S., T.M., and D.K. are current AbbVie employees and may hold AbbVie stock or options. Y.S. and Y.S.O. are current or former Enanta employees and may hold Enanta stock or options. The design and study conduct for this research were provided by AbbVie and Enanta. AbbVie and Enanta participated in the interpretation of the data and review and approval of the publication.
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
The authors would like to thank the patients and their families as well as study site staff who participated in the clinical trials of paritaprevir.
Naggie S, Muir A (2017) Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med 68:345–358CrossRefGoogle Scholar
Grillot A-L, Farmer L, Rao B et al (2011) Discovery and development of telaprevir. Anti-Cancer Drugs 209–224Google Scholar
Njoroge F, Chen K, Shih N-Y et al (2008) Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 41:50–59CrossRefGoogle Scholar
Kempf D, Klein C, Chen H-J et al (2007) Pharmacokinetic enhancement of the hepatitis C virus protein inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 18:163–167CrossRefGoogle Scholar
Jacobson I, McHutchison J, Dusheiko G et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–2416CrossRefGoogle Scholar
Poordad F, McCone Jr J, Bacon B et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195–1206CrossRefGoogle Scholar
Lamarre D, Anderson P, Bailey M et al (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186–189CrossRefGoogle Scholar
Stoltz J, Stern J, Huang Q et al (2011) A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061. Toxicol Pathol 39:496–501CrossRefGoogle Scholar
Gower E, Estes C, Blach S et al (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61(Suppl):S45–S57CrossRefGoogle Scholar
Fried M, Shiffman M, Reddy R et al (2002) Peginterferon alfa-2a plus ribovirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982CrossRefGoogle Scholar
Manns M, McHutchinson J, Gordon S et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958–965CrossRefGoogle Scholar
Lohmann V, Hoffmann S, Herian U et al (2003) Viral and celluar determinants of hepatitis C virus RNA replication in cell culture. J Virol 77:3007–3019CrossRefGoogle Scholar
Llinas-Brunet M, Bailey M, Ghiro E et al (2004) A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors. J Med Chem 47:6584–6594CrossRefGoogle Scholar
Scola P, Wang A, Good A et al (2014) Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem 57:1708–1729CrossRefGoogle Scholar
Llinas-Brunet M, Bailey M, Fazal G (2000) Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg Med Chem Lett 10:2267–2700PubMedPubMedCentralGoogle Scholar
Pilot-Matias T, Tripathi R, Cohen D et al (2015) In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988–997CrossRefGoogle Scholar
Konstantinidis A, Richardson P, Kurtz K et al (2007) Longer wavelength fluorescence energy transfer depsipeptide substrates for hepatitis C virus NS3 protease. Anal Biochem 368:156–167CrossRefGoogle Scholar
Morrison J, Stone S (1985) Approaches to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors. Comments Mol Cell Biophys 2:347–368Google Scholar
Kempf D, Marsh K, Kumar G et al (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654–660CrossRefGoogle Scholar
Sham H, Kempf D, Molla A et al (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42:3218–3224CrossRefGoogle Scholar
Shulman N, Zolopa A, Havlir D et al (2002) Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 46:3907–3916CrossRefGoogle Scholar
Hassner A, Patchornik G, Pradhan T et al (2007) Intermolecular electrophilic O-amination of alcohols. J Org Chem 72:658–661CrossRefGoogle Scholar
Berger K, Lagace L, Triki I et al (2013) Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study. Antimicrob Agents Chemother 57:4928–4936CrossRefGoogle Scholar
Lim S, Qin X, Susser S et al (2012) Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy in hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother 56:271–279CrossRefGoogle Scholar
McPhee F, Friborg J, Levine S et al (2012) Resistance analysis of the hepatitis C virus NS3 protease inhibitor asuneprevir. Antimicrob Agents Chemother 56:3670–3681CrossRefGoogle Scholar
Reesink H, Fanning G, Farha K et al (2010) Rapid HCV-RNA decline with once daily TMC435: a phase 1 study in healthy volunteers and hepatitis C patients. Gastroenterology 138:913–921CrossRefGoogle Scholar
Sarrazin C, Kieffer T, Bartels D et al (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with protease inhibitor telaprevir. Gastroenterology 132:1767–1777CrossRefGoogle Scholar
Susser S, Welsch C, Wang Y et al (2009) Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709–1718CrossRefGoogle Scholar
Lenz O, Vijgen L, Berke J et al (2013) Virologic response and characterization of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 58:445–451CrossRefGoogle Scholar
McPhee F, Sheaffer A, Friborg J et al (2012) Preclinical profile and characterization of hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 56:5387–5396CrossRefGoogle Scholar
Menon R, Klein C, Podsadecki T et al (2016) Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharm 81:929–940CrossRefGoogle Scholar
Poordad F, Lawitz E, Kowdley K et al (2013) Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368:45–53CrossRefGoogle Scholar
Kowdley K, Lawitz E, Poordad F et al (2014) Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222–232CrossRefGoogle Scholar
Feld J, Kowdley K, Coakley E et al (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1594–1603CrossRefGoogle Scholar
Ferenci P, Bernstein D, Lalezari J et al (2014) ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370:1983–1982CrossRefGoogle Scholar
Zeuzem S, Foster G, Wang S et al (2018) Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378:354–369CrossRefGoogle Scholar